United States · Platforms & data · Briefing.com

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

Published by Briefing.com · United States 14 d ago

Vaxcyte (PCVX) is soaring today after announcing topline results from the pivotal Phase 3 OPUS-1 trial evaluating VAX-31. VAX-31 is PCVX's investigational 31-valent pneumococcal…

Read the full article on Briefing.com Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.briefing.com)

Also worth reading

MarketBeat

Franco-Nevada Co. (FNV.TO) - What Are Researchers Thinking About This Stock?

Seeking Alpha

RLI Non-GAAP EPS of $0.86 beats by $0.33, revenue of $476.9M beats by $9.8M

The Motley Fool

SpaceX Wants a 32-Mile Pipeline Tied Into Energy Transfer's and Kinder Morgan's Florida System. Does It Matter for Either Pipeline Stock?

MarketWatch

Colleges raced to build massive computer-science departments. Now the boom is turning to bust.

Investing.com

First Solar leads green energy stocks on value and free cash flow

CNBC